Zoetis Announces Pricing of $1.35 Billion of Senior Notes
November 08 2022 - 5:20PM
Business Wire
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to
sell $1.35 billion of senior notes, consisting of $600 million
aggregate principal amount of 5.400% senior notes due 2025 and $750
million aggregate principal amount of 5.600% senior notes due 2032,
in an underwritten public offering.
Zoetis intends to use the net proceeds to repay the principal of
its 3.250% senior notes due 2023 in the aggregate principal amount
of $1.35 billion and the remainder, if any, for general corporate
purposes. The offering is expected to close on November 16, 2022,
subject to customary closing conditions.
Barclays Capital Inc., BofA Securities, Inc., Citigroup Global
Markets Inc., J.P. Morgan Securities LLC and MUFG Securities
Americas Inc. are acting as joint book-running managers of the
underwriters. The final prospectus supplement and accompanying
prospectus, when available, may be accessed through the SEC’s
website at www.sec.gov. Alternatively, the issuer, the
underwriters or any dealer participating in the offering will
arrange to send the prospectus and prospectus supplement upon
request by calling Barclays at 1-888-603-5847, BofA Securities at
1-800-294-1322, Citigroup at 1-800-831-9146, J.P. Morgan at
212-834-4533 and MUFG at 1-877-649-6848.
These securities are offered pursuant to a registration
statement that has become effective under the Securities Act of
1933, as amended. These securities are only offered by means of the
prospectus supplement and prospectus relating to the offering. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any offer or
sale of these securities in any state or other jurisdiction, where
the offer, solicitation or sale of these securities would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Zoetis
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After 70 years innovating ways to
predict, prevent, detect, and treat animal illness, Zoetis
continues to stand by those raising and caring for animals
worldwide -- from livestock farmers to veterinarians and pet
owners. The company’s leading portfolio and pipeline of medicines,
vaccines, diagnostics and technologies make a difference in over
100 countries.
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to future actions,
business plans or prospects, product and supply chain disruptions,
the impact of the COVID-19 pandemic, future operating or financial
performance, risks or expectations related to indebtedness and
financial results and other future events. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, including in the sections thereof captioned
“Forward-Looking Statements and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
ZTS-COR ZTS-IR ZTS-FIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108006251/en/
Media Contacts: Bill Price
1-973-443-2742 (o) william.price@zoetis.com Kristen Seely
1-973-443-2777 (o) kristen.seely@zoetis.com
Investor Contacts: Steve Frank
1-973-822-7141 (o) steve.frank@zoetis.com Nick Soonthornchai
1-973-443-2792 (o) nick.soonthornchai@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024